The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade
The high level of tumor cell lysis and increased expression of pro-inflammatory cytokines induced by the Fc-based bsAbs suggest a novel approach for the treatment of pancreatic, endometrial and breast cancer.
Authors
- Wiktoria Gąsior
- Tomasz Sitar
- Louis Boon (ORCID: https://orcid.org/0000-0002-0937-9171)
- Michał Mikitiuk (ORCID: https://orcid.org/0000-0002-7152-9492)
- Tad A. Holak (ORCID: https://orcid.org/0000-0001-9369-6024)
- Aleksandra Hec (ORCID: https://orcid.org/0000-0002-3669-0600)
- Maja Myrcha
- Jan Barczyński (ORCID: https://orcid.org/0000-0002-1335-2959)
- Przemysław Bielski
- Kamil Rykała
Institutions
- Jagiellonian University (PL)
- Pure Biologics (Poland) (PL)
- ZRE Gdańsk (Poland) (PL)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1486799
- Citations
- 4
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 5.44